Calquence tablet formulation approved in the EU for patients with chronic lymphocytic leukaemia
Tablet formulation can be co-administered with gastric acid-reducing agents allowing greater patient and physician choice.Approval based on ELEVATE-PLUS trials which showed bioequivalence and consistent dosing vs. current capsule.AstraZeneca’s tablet formulation of Calquence (acalabrutinib) has been approved in the European Union (EU) for the treatment of adult patients with chronic lymphocytic leukaemia (CLL). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use and is based on results from the ELEVATE-PLUS trials